Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: August 4, 2022
Reporting Period: Second Quarter ended June 30, 2022
This filing serves as a notification that the Company issued a press release regarding its financial results for the second quarter of 2022. The detailed financial data is contained in the press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover document for the 8-K filing and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1) but are not present in the source text provided.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended June 30, 2022.
Guidance, Outlook, and Risks
- Conference Call: The Company hosted a conference call on August 4, 2022, at 4:30 p.m. Eastern Time to present business and financial results. A webcast was archived on the Company's website.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties, including those detailed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
- Legal Disclaimer: Information furnished under Item 2.02 and Item 9.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2022 revenue, net income, and cash flow figures.
- Access the archived webcast on the Company's website for management commentary on the results.
- Consult the Form 10-K filed on April 13, 2022, for a comprehensive list of risk factors referenced in this filing.
- Verify the Company's liquidity position and debt obligations in the full quarterly report, as they are not detailed in this 8-K summary.